Loading...

Biotinylated Recombinant Human CD22-Fc Chimera (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
SIGLEC2, CD22 Antigen, BL-CAM, B-Cell Receptor CD22
Ave. Rating
Submit a Review
Product Citations
publications
Human_CD22_CF_RECOM_1_030222
Biotinylated recombinant human CD22-Fc chimera inhibits the proliferation of human B cells induced by LPS in a dose-dependent manner. The ED50 for this effect is 1 – 6 µg/mL.
  • Human_CD22_CF_RECOM_1_030222
    Biotinylated recombinant human CD22-Fc chimera inhibits the proliferation of human B cells induced by LPS in a dose-dependent manner. The ED50 for this effect is 1 – 6 µg/mL.
  • Human_CD22_CF_RECOM_2_030222
    Stability Testing for Biotinylated Recombinant Human CD22-Fc Chimera. Biotinylated recombinant human CD22-Fc chimera was aliquoted in PBS, pH 7.2 at 0.2 mg/mL and one aliquot was kept at 4°C (control), and another was frozen and thawed four times (4x Freeze/Thaw). After this procedure, the samples were tested for their ability to inhibit the proliferation of human B cells induced by LPS in a dose-dependent manner. The ED50 for this effect is 1 – 6 µg/mL.
Cat # Size Price Quantity Check Availability Save
797604 25 µg £197
Check Availability


Need larger quantities of this item?
Request Bulk Quote
797606 100 µg £586
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

CD22 is a type I transmembrane protein of 140 kD expressed in B cells. The extracellular domain (ECD) contains seven Ig domains with 12 recognized N-linked glycosylation sites. CD22 binds to α2,6-linked sialic acid (Sias) ligands connected to galactose. The Ig domain 1 (d1) recognizes Sias containing α2,6-linkages. CD22 regulates signaling through its intracellular inhibitory ITIMs domains. The regulation of B cell function by CD22 is performed through sialic ligand-dependent and -independent mechanisms. CD22 regulates the migration of recirculating B cells to the bone marrow. CD22 knockdown mice present B cell impaired survival, increase of B cell turnover, and decrease of marginal zone B cells. In addition, CD22-deficient B cells show hyperactivation in response to TLR (TLR3, TLR4, and TLT9) ligands. CD22 ligation with anti-CD22 affects the response to TLR7. Under this condition, the B cell differentiation into plasmablasts is limited, and the B cell production of cytokine by the stimulation of TLR7 or TLR9 is affected. B-cell leukemias and lymphomas express CD22, and it has been used as a target for Ab-dependent therapies. Epratuzumab (Emab) is a humanized anti-CD22 used in clinical trials of B-cell Non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL). Emab has been explored in clinical trials for SLE and primary Sjogren’s syndrome. 

Product Details
Technical Data Sheet (pdf)

Product Details

Source
Human CD22-Fc, amino acid (Asp20 – Arg687) (Accession: P20273), with a C-terminal human IgG1 (Pro100-Lys330), and an Avi-tag, was expressed in CHO cells. Human CD22-Avi tag was site-specifically biotinylated by enzyme BirA.
Molecular Mass
The 931 amino acid recombinant protein has a predicted molecular mass of approximately 104.3 kD. The protein migrates at approximately 120 kD and 240 kD by SDS-PAGE in DTT-reduced and non-reduced conditions, respectively. The predicted N-terminal amino acid is Asp.
Purity
> 95%, as determined by Coomassie stained SDS-PAGE
Formulation
0.22 µm filtered protein solution is in PBS pH 7.2
Endotoxin Level
Less than 0.1 EU per µg cytokine as determined by the LAL method
Concentration
25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
Biotinylated recombinant human CD22-Fc chimera inhibits the proliferation of human B cells induced by LPS in a dose dependent manner. The ED50 for this effect is 1 – 6 µg/mL.
Application

Bioassay
Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Antigen Details

Structure
Dimer
Distribution

B cells

Function
Mediates B cell/B cell interactions, regulates B cell functions, inhibitory co-receptor of BCR, regulate negatively TLRs signaling in B cells.
Interaction
B cells, B cell lines, DC
Ligand/Receptor
CD45RO, CD75
Bioactivity
Biotinylated recombinant human CD22-Fc chimera inhibits the proliferation of human B cells induced by LPS in a dose-dependent manner.
Cell Type
B cells
Biology Area
Adaptive Immunity, Cell Adhesion, Cell Biology, Cell Proliferation and Viability, Immuno-Oncology, Immunology, Innate Immunity
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors, Soluble Receptors
Antigen References
  1. Willson GL, et al. 1991. J Exp Med. 173:137-46.
  2. Santos L, et al. 2008. J Immunol. 180:4561-9.
  3. Nirihito K, et al. 2011. J Innate Immune. 3:411.
  4. Poe JC and Tedder TF. 2012. Trends Immunol. 33:413-20.
  5. Muller J, et al. 2013. Proc Natl Acad Sci USA. 110:12402-7.
  6. Oreno-Orbea J, et al. 2017. Nat Commun. 8:764.
  7. Giltiay NV, et al. 2017. Arthritis Res Ther. 19:91.
  8. Clark EA and Giltiay NV. 2018. Front Immunol. 9:2235.
  9. Gottenberg JE, et al. 2018. Arthr Rheumatol. 70:763-773.

 

Gene ID
933 View all products for this Gene ID
UniProt
View information about CD22 on UniProt.org
Go To Top Version: 1    Revision Date: 03/02/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account